Previous studies have indicated that ZDHHC11 and ZDHHC11B play critical roles in maintaining the oncogenic MYC-miR-150-MYB axis in Burkitt’s lymphoma, and ZDHHC11 may be a biomarker to identify high-risk bladder cancer patients with disease progression (Yamamoto et al., 2007; Dzikiewicz-Krawczyk et al., 2017). This evidence concerns the gene ZDHHC11B and urinary bladder carcinoma.